Johnson & Johnson reports MedTech miss. Johnson & Johnson stock falls 2.04 percent

Published on 10/16/2026 at 10:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MedTech sales reached USD 8.6 billion in third quarter 2026. Johnson & Johnson stock costs EUR 226.58 on October 16, 2026, 2.04 percent below Xetra.

Johnson & Johnson updates guidance

On October 13, 2026, MedTech sales rose 2.5 percent to USD 8.6 billion.
Reported 2026 sales guidance midpoint increased to USD 101.2 billion.
Johnson & Johnson stock trades at EUR 226.58 at 10:37 a.m. CEST at Lang & Schwarz on October 16, 2026, 2.04 percent below the Xetra close of October 15, 2026.

Isometric 3D illustration of a pharmaceutical campus with four color-coded sectors: a blue research lab with DNA helix, a grey manufacturing floor with conveyor belts, a teal medical devices room with surgical equipment, and a warm white consumer health s — Johnson Konzern isometrisch, US4781601046 mit Forschung Produktion Medical Devices und Consumer Health, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 226.58 at Lang & Schwarz on October 16, 2026 at 10:37 a.m. CEST, down 2.04 percent versus the Xetra close of October 15, 2026 at EUR 231.30. The company reported third-quarter results and raised its 2026 guidance on October 13, 2026, according to Johnson & Johnson.

Three results dates show the reset

On July 29, 2026, the prior reported-sales guidance midpoint was USD 101.1 billion; on October 13, 2026, third-quarter reported sales reached USD 25.399 billion versus USD 23.993 billion a year earlier, a 5.9 percent increase; on October 13, 2026, the new reported-sales guidance midpoint was USD 101.2 billion, according to Johnson & Johnson. The sequence shows a modest guidance lift despite a sharp decline in reported earnings caused by special items.

What does MedTech mean for growth?

MedTech sales rose 2.5 percent to USD 8.6 billion in the third quarter of 2026, below the USD 8.71 billion analyst estimate cited by CNBC. Innovative Medicine sales reached USD 16.757 billion, up 7.7 percent from the prior-year quarter, giving the drug business a larger growth contribution than MedTech. Johnson & Johnson reported adjusted earnings per share of USD 2.59 for the quarter, while GAAP diluted earnings per share were USD 0.09 after litigation and acquisition-related charges.

Next reporting date is January 26, 2027

The next report is expected on January 26, 2027, according to Yahoo Finance. That date gives investors a later checkpoint for the revised sales outlook and the balance between Innovative Medicine and MedTech.

Stock trades below the Xetra close

Johnson & Johnson was trading at EUR 226.58 at Lang & Schwarz on October 16, 2026 at 10:37 a.m. CEST, 2.04 percent below the Xetra close of October 15, 2026 at EUR 231.30. The decline keeps the market response negative even as the company lifted its full-year sales and adjusted earnings guidance.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.